← 治験一覧に戻る
AB122プラットフォーム調査
基本情報
- NCT ID
- NCT04999761
- ステータス
- 募集中
- 試験のフェーズ
- 第1相
- 試験タイプ
- 介入
- 目標被験者数
- 917
- 治験依頼者名
- Taiho Pharmaceutical Co., Ltd.
概要
This is a phase 1, non-randomized open-label, multicenter platform study designed to evaluate the tolerability and safety of AB122 in patients with malignancies specified in each cohort.
対象疾患
Advanced or Metastatic Solid TumorPancreatic Ductal AdenocarcinomaColorectal CancerNon-small Cell Lung CancerGastric CancerAlveolar Soft Part SarcomaEsophageal CancerHead and Neck CancerBiliary Tract Cancer
介入
AB122(DRUG)
AB122(DRUG)
TAS-116(DRUG)
AB122(DRUG)
TAS-116(DRUG)
AB122(DRUG)
TAS-116(DRUG)
AB122(DRUG)
TAS-120(DRUG)
AB122(DRUG)
TAS-115(DRUG)
AB122(DRUG)
TAS-115(DRUG)
AB122(DRUG)
TAS-102(DRUG)
Ramucirumab(DRUG)
AB122(DRUG)
TAS-102(DRUG)
Bevacizumab(DRUG)
AB122(DRUG)
AB122(DRUG)
TAS-120(DRUG)
Fluorouracil(DRUG)
Cisplatin(DRUG)
AB122(DRUG)
TAS-120(DRUG)
AB154(DRUG)
AB122(DRUG)
TAS-120(DRUG)
Fluorouracil(DRUG)
Carboplatin(DRUG)
Cisplatin(DRUG)
AB122(DRUG)
TAS-120(DRUG)
AB154(DRUG)
AB122(DRUG)
TAS-120(DRUG)
Carboplatin(DRUG)
nab-Paclitaxel(DRUG)
AB122(DRUG)
TAS-120(DRUG)
Cisplatin(DRUG)
Gemcitabine(DRUG)
AB122(DRUG)
TAS-120(DRUG)
nab-Paclitaxel(DRUG)
Gemcitabine(DRUG)
依頼者（Sponsor）
大鵬薬品工業株式会社(INDUSTRY)